Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company’s non ...
WREX

Routine prenatal test revealed her ‘hidden cancer.’ A study suggests what doctors should watch for

Instead, she enrolled in a study at the National Institutes of Health that involved examining women who received abnormal prenatal DNA-sequencing test results like hers. Through that research, Khorram ...